Envoy Medical Completes Pivotal Trial Enrollment; Secures $30M Financing
Envoy Medical reported its first quarter 2026 financial results and announced landmark achievements, including the completion of enrollment in its pivotal clinical trial for the Acclaim® fully implanted cochlear implant. The company also secured transformational financing of up to $78.0 million and expanded its intellectual property portfolio to 47 patents. Early clinical data from the pivotal study showed promising improvements in word recognition and quality-of-life scores, with all 56 patients activated and the first three reaching their 12-month endpoint. For Q1 2026, Net Revenue was $39 thousand, and R&D expenses increased to $3,642 thousand, reflecting increased clinical trial activity, while the cash position significantly improved to $25,251 thousand.
Key Highlights
- Pivotal clinical trial enrollment for Acclaim® cochlear implant completed with 56th patient implanted on March 11, 2026.
- Closed an upsized public offering for up to $78.0 million, including $30.0 million gross proceeds at closing.
- Expanded global IP portfolio to 47 patents, securing three new patents in February 2026.
- Interim six-month clinical data from first 10 patients showed mean CNC word recognition improved from 15.2% to 39.2%.
- All 56 pivotal trial patients activated, with first three patients reaching 12-month endpoint.
- Net Revenue for Q1 2026 was $39 thousand.
- R&D expenses for Q1 2026 increased by $894 thousand to $3,642 thousand due to clinical trial activity.
- Cash balance was approximately $25,251 thousand as of March 31, 2026.